Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Total Liabilities (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Total Liabilities data on record, last reported at $42.6 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 72.45% year-over-year to $42.6 million; the TTM value through Sep 2025 reached $42.6 million, up 72.45%, while the annual FY2024 figure was $25.0 million, 30.76% down from the prior year.
  • Total Liabilities reached $42.6 million in Q3 2025 per CAPR's latest filing, up from $28.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $47.7 million in Q1 2023 and bottomed at $6.4 million in Q3 2021.
  • Average Total Liabilities over 5 years is $29.3 million, with a median of $31.0 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: soared 504.94% in 2022, then tumbled 38.14% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $10.0 million in 2021, then skyrocketed by 284.54% to $38.3 million in 2022, then dropped by 5.68% to $36.1 million in 2023, then tumbled by 30.76% to $25.0 million in 2024, then surged by 70.16% to $42.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $42.6 million in Q3 2025, $28.6 million in Q2 2025, and $26.1 million in Q1 2025.